Kellane Howell
Acute Care · West Palm Beach, FLNPI 1912372905
Payments from drug & device makers
Across 137 payments — averaging $28.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$808
- AbbVie$486
- Neurocrine Biosciences, Inc.$402
- E.r. Squibb & Sons, L.L.C.$379
- Johnson & Johnson$282
- plus $450 from 5 others
What the payments were for
- Food & beverage$3,78197%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 30 | $1,085 |
| Otsuka America Pharmaceutical, Inc. | 21 | $808 |
| AbbVie | 26 | $486 |
| Neurocrine Biosciences, Inc. | 24 | $402 |
| E.r. Squibb & Sons, L.L.C. | 13 | $379 |
| Johnson & Johnson | 10 | $282 |
| Alkermes, Inc. | 4 | $130 |
| Biogen | 1 | $120 |
| Vanda Pharmaceuticals Inc. | 3 | $108 |
| Lundbeck LLC | 4 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,892 in reported general payments places this provider in the 90th percentile of 1,150 acute care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 218 | $737,341 |
| Invega TrinzaPaliperidone Palmitate | 50 | $477,444 |
| Austedo XrDeutetrabenazine | 52 | $375,214 |
| AustedoDeutetrabenazine | 39 | $234,756 |
| Abilify MaintenaAripiprazole | 55 | $160,483 |
| IngrezzaValbenazine Tosylate | 15 | $121,344 |
| AristadaAripiprazole Lauroxil | 25 | $80,459 |
| RexultiBrexpiprazole | 40 | $62,877 |
| VraylarCariprazine Hcl | 38 | $52,708 |
| CaplytaLumateperone Tosylate | 23 | $40,450 |
| Fluphenazine Hcl | 28 | $11,605 |
| Quetiapine Fumarate | 215 | $10,657 |
| Paliperidone ErPaliperidone | 53 | $8,942 |
| Lurasidone Hcl | 55 | $8,449 |
| Aripiprazole | 91 | $7,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $282 | $1,214,785268 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,085 | $609,97191 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $808 | $223,36095 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $402 | $121,34415 claims |
| Alkermes, Inc.Aristada | $130 | $80,45925 claims |
| AbbVieVraylar | $486 | $52,70838 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $24 | $40,45023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,150 acute care providers in Florida.
Other acute care in West Palm Beach
- Melisa WilsonOrlando$3.6M
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
- Julie ElliottWinter Haven$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.